Related Experiment Video
Updated: Feb 4, 2026
A Gut-on-a-Chip Model to Study the Gut Microbiome-Nervous System Axis
Published on: July 28, 2023
Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to
Melanie Schirmer1, Lee Denson2, Hera Vlamakis3
1The Broad Institute of MIT and Harvard, Infectious Disease and Microbiome, Cambridge, MA 02142, USA; Harvard T.H. Chan School of Public Health, Biostatistics Department, Boston, MA 02115, USA.
Insights
The gut microbiome influences ulcerative colitis (UC) progression. Changes in gut bacteria, like oral cavity bacteria expansion, correlate with UC severity and treatment response, aiding future therapies.
Area of Science:
- Gastroenterology
- Microbiology
- Immunology
Background:
- Ulcerative colitis (UC) treatment is challenging due to incomplete patient responses.
- Predicting disease progression and optimizing therapy requires further understanding of UC's underlying mechanisms.
Purpose of the Study:
- To investigate the role of the gut microbiome in the disease course of pediatric, new-onset, treatment-naive ulcerative colitis (UC) patients.
- To identify microbial signatures associated with disease severity, treatment response, and host-microbial interactions in UC.
Main Methods:
- Analysis of fecal and rectal biopsy samples from 405 pediatric UC patients over a 1-year follow-up period.
- Microbial taxonomic composition was assessed using the PROTECT (Predicting Response to Standardized Colitis Therapy) Study data.
- Correlation of microbial changes with clinical outcomes, disease severity markers, and serological data.
Main Results:
- Depletion of beneficial gut microbes and an increase in oral bacteria were linked to higher baseline UC severity.
- Species-specific temporal microbial shifts correlated with remission or refractory disease, suggesting therapeutic efficacy.
- Increased microbiome variability preceded colectomy, and microbial markers associated with serological markers indicated host-microbial interactions.
Conclusions:
- Gut microbiome composition and dynamics are critical factors in pediatric ulcerative colitis course.
- Microbial profiles can predict disease severity and may indicate response to therapy.
- Understanding host-microbial interactions offers potential for developing improved UC treatments.
Abstract:
Evaluating progression risk and determining optimal therapy for ulcerative colitis (UC) is challenging as many patients exhibit incomplete responses to treatment. As part of the PROTECT (Predicting Response to Standardized Colitis Therapy) Study, we evaluated the role of the gut microbiome in disease course for 405 pediatric, new-onset, treatment-naive UC patients. Patients were monitored for 1 year upon treatment initiation, and microbial taxonomic composition was analyzed from fecal samples and rectal biopsies. Depletion of core gut microbes and expansion of bacteria typical of the oral cavity were associated with baseline disease severity. Remission and refractory disease were linked to species-specific temporal changes that may be implicative of therapy efficacy, and a pronounced increase in microbiome variability was observed prior to colectomy. Finally, microbial associations with disease-associated serological markers suggest host-microbial interactions in UC. These insights will help improve existing treatments and develop therapeutic approaches guiding optimal medical care.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution